Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications

    February 2023 in “ Advances in Therapy ”
    Peter C Taylor, Thomas Bieber, Rieke Alten … Andreas Wollenberg
    Studysummary This study found that patients with rheumatoid arthritis, atopic dermatitis, and alopecia areata receiving baricitinib had low incidence rates of adverse events, especially among low-risk individuals, with varying rates among those at higher risk.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on link.springer.com →
    Discuss this study in the Community →

    Research cited in this study 6

    1. Integrated Safety Analysis of Baricitinib in Adults With Severe Alopecia Areata From Two Randomized Clinical Trials British journal of dermatology/British journal of dermatology, Supplement · 2022
    2. Two Phase 3 Trials of Baricitinib for Alopecia Areata The New England Journal of Medicine · 2022
    3. Comorbidities in Alopecia Areata: A Systematic Review and Meta-Analysis Journal of The American Academy of Dermatology · 2018
    4. Cancer Risk by the Subtype of Alopecia Scientific Reports · 2018
    5. Cancer Risk in Patients with Alopecia Areata: A Nationwide Population-Based Matched Cohort Study Cancer Medicine · 2018
    6. Cardiovascular Risk in Patients with Alopecia Areata: A Propensity-Matched Retrospective Analysis Journal of the American Academy of Dermatology · 2016